Technology/ Title	DBPR117: A Precision Medicine (mAb) Targeting RSPO3/Wnt-Mediated Tumorigenesis	
Technology Type	☐Biotechnology	☐Device/Diagnostics
	■Pharmaceutical	☐Others:_____-
Contact Person	Name: Hua-Hsuan Liang	Title: Acting Section Chief
	Telephone(work): 886-37-206166#33206	Mobile:
	Email: huahsuan@nhri.edu.tw	
Link	http://ibpr.nhri.org.tw/zhtw/wp-content/uploads/2018/07/New-2018_NCR-of-DBPR117.pdf	
Technology Description	R-spondin 3 (RSPO3) was identified as a novel key modulator of cancer development and a potential target for treatment of cancers. Therefore, we selected RSPO3 as a therapeutic target and discovered a potent neutralizing antibody, DBPR117, that was shown to have anti-cancer activity. DBPR117 is a humanized IgG1 that is capable of neutralizing the aberration of RSPO3-mediated Wnt/β-catenin signaling. DBPR117 is comparable with rosmantuzumab (131R010), an antibody developed by OncoMed, as shown in a number of assays including binding assays, *in vitro* ligand neutralization and wound healing assays, and *in vivo* PDX (patient-derived xenograft) or CDX (cell line-derived xenograft) models.	
Intellectual Property	Patent title: Anti-RSPO3 antibodies, compositions, methods and uses Appl No. TW: 107143984 PCT: PCT/US18/64236	
Key Publications	N/A	
Business Opportunity	DBPR117 can inhibit cancer stemness and DBPR117 will be examined for activity in reducing RSPO3-mediated tumorigenesis and metastasis. DBPR117 will be developed to cover a wide range of cancers along with companion diagnostics that can identify patients who are most likely to benefit from DBPR117, alone or in combination with other agents.	